NCT04883996View on ClinicalTrials.gov

A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

August 30, 2021

Conditions
HyperopiaMyopia
Interventions
DRUG

1% EXP039

1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),

OTHER

Saline control

Saline

Trial Locations (1)

91702

Canyon City Eyecare, Azusa

Sponsors

Collaborators (1)

Nevakar, Inc.
All Listed Sponsors
collaborator

Nevakar, Inc.

INDUSTRY

lead

Canyon City Eyecare

OTHER

NCT04883996 - A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia | Biotech Hunter | Biotech Hunter